Cencora Maintains MSO Investment Focus Amid ASP Regulation in Q3 2026 Earnings

Cencora’s MSO Investment and Capital Allocation Outlook

1. MSO investment can continue despite ASP regulatory uncertainty

Management’s answer is yes: Cencora intends to continue investing in the MSO businesses despite proposed changes to ASP-related rules and pricing dynamics. Erin explicitly said the company remains confident in the long-term outlook for community physicians, including reimbursement, and therefore intends to continue investing in the MSO space. ¹

However, the investment strategy is becoming more selective rather than broadly expansionary:

• Retina and oncology remain the core MSO targets. Cencora plans to focus on accretive tuck-in acquisitions for Retina Consultants of America, or RCA, and OneOncology. ¹
• The strategy remains pharmaceutical-centric. Management currently views oncology and retina as the only specialties that meet its definition of pharmaceutical-centric MSO opportunities. ¹
• Cencora does not currently plan to enter additional disease states through MSOs. It will continue serving specialty products across different sites of care, but it does not intend to build MSOs in other specialties in the near term. ¹
• The door is not permanently closed. Management could pursue another specialty in the future if it were physician-administered, specialty-oriented, and sufficiently pharmaceutical-centric, but executives said they do not see such an opportunity in the near term. ¹

The implication is that ASP regulation does not invalidate the MSO thesis, but it does reinforce the need for disciplined underwriting. Cencora is emphasizing businesses where its pharmaceutical distribution, GPO, manufacturer-service, and community-physician capabilities can create value beyond simple exposure to drug reimbursement. This is consistent with management’s description of a three-phase MSO value-creation model: integration into Cencora, sharing capabilities such as clinical-trial infrastructure, and eventually developing new services and analytics for physicians and pharmaceutical manufacturers. ²

2. The current evidence supports continued MSO investment, but not an aggressive change in scope

The operating evidence presented on the call was favorable:

• OneOncology outperformed expectations in the quarter, demonstrating the platform’s ability to attract physicians. ³
• OneOncology’s operating income was modestly above initial expectations, although the company continues to expect the business to be neutral to adjusted EPS net of financing over a 12-month period. ⁴
• Management said both OneOncology and RCA were performing well, while acknowledging that the broader platform-sharing and new-services opportunities remain in the early stages. ²⁴
• Excluding the Florida Cancer loss and the OneOncology contribution, operating income growth in the underlying business accelerated to double digits from 7% in the prior quarter. ³

These results support continued investment, particularly through smaller tuck-ins and physician additions. They do not, however, support assuming that all MSO expansion will immediately increase earnings. OneOncology is still expected to be adjusted-EPS neutral net of financing over a 12-month period, and the company characterizes the larger platform synergies as future opportunities rather than fully realized benefits. ⁴²

3. Eva’s guidance philosophy is continuity, not a fundamental reset

Eva indicated that her approach to guidance would be based on a disciplined internal process reflecting the actual businesses and their operating expectations. She also said she intends to preserve Cencora’s long record of meeting or exceeding expectations. ⁵

That suggests the likely adjustment is process-oriented rather than directional:

• Guidance will continue to be grounded in operating performance and internal business-level expectations. ⁵
• The objective is to maintain credibility and avoid guidance that is either overly conservative or aspirational. Eva said the process is supported by a long-tenured team with deep expertise in Cencora’s businesses. ⁵
• Management did not provide a new quantified ASP sensitivity or say that the proposed ASP changes would require a change to the company’s long-term outlook. The excerpts therefore do not support modeling a specific ASP-related earnings reduction at this stage. ⁵⁶
• Cencora reaffirmed confidence in its long-term guidance and said it expects to provide fiscal 2027 guidance on the November earnings call. ⁷⁸⁹

The fiscal 2026 update also showed that management was willing to raise guidance when operating performance and capital actions supported it: adjusted EPS guidance increased to $17.75-$17.95 from $17.70-$17.90, while consolidated operating-income growth guidance increased to 13%-14%. ¹⁰ That increase was accompanied by a $1 billion share repurchase during the quarter, which reduced expected diluted shares outstanding to approximately 194 million and contributed to the higher EPS outlook. ¹⁰⁹

4. Capital deployment will remain balanced across reinvestment, M&A, buybacks, and dividends

Eva described four continuing capital-allocation priorities:

1. Internal investment in the business
2. Strategic M&A
3. Opportunistic share repurchases
4. A reasonable and growing dividend ⁵

Her stated goal is to build on the existing framework while increasing flexibility to invest in growth and create shareholder value. ⁵ This indicates that Cencora is not shifting capital exclusively toward MSOs or exclusively toward buybacks. Instead, capital deployment will remain portfolio-based and dependent on relative returns, strategic fit, and valuation.

The recent $1 billion repurchase demonstrates that buybacks remain available when management views them as attractive, but the resulting lower interest income also increased expected net interest expense from approximately $485 million to approximately $490 million. ⁹ In other words, repurchases can improve per-share earnings through a lower share count, but they also consume cash that could otherwise support acquisitions or internal investment and can reduce interest income. ¹⁰⁹

5. Expected mix across businesses

The business mix implied by the commentary is as follows:

This mix points to a pharmaceutical-centric portfolio strategy, not a broad healthcare-services conglomerate strategy. Cencora appears willing to invest where its distribution platform, specialty products, manufacturer relationships, and physician networks reinforce one another, while using divestitures or strategic alternatives for businesses that fit less directly with the core model. ¹¹¹⁸

Bottom line

Cencora can continue investing in MSOs under the current ASP environment, but the company is signaling selective expansion rather than indiscriminate growth. The practical focus is on accretive tuck-ins and physician recruitment within oncology and retina, where management believes the businesses are most closely aligned with pharmaceutical-centric economics. ¹²

Eva’s arrival does not appear to represent a change in strategic direction. Her guidance philosophy emphasizes disciplined, business-based forecasting and continued delivery against expectations, while her capital-allocation framework preserves flexibility among internal investment, strategic M&A, buybacks, and dividends. ⁵ The key unresolved issue is the ultimate economic effect of proposed ASP-rule changes: the excerpts provide no quantified impact, so the appropriate interpretation is that Cencora is monitoring the risk but has not yet altered its MSO strategy or long-term guidance on the basis of a measured ASP impact. ¹⁶⁷